ArticleOncology letters2015
Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Association of RAGE rs1800625 Polymorphism and Cancer Risk: A Meta-Analysis of 18 Case-Control Studies.Medical science monitor : international medical journal of experimental and clinical research · 2019Pooled it
- Serum-Soluble Receptor for Advanced Glycation End Products as a Potential Biomarker in Lung Cancer Patients.Journal of personalized medicine · 2026Article
- Advanced Glycation End Products in Disease Development and Potential Interventions.Antioxidants (Basel, Switzerland) · 2025Review
- Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma.Journal of cancer research and clinical oncology · 2024Article
- The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics.Journal of cellular and molecular medicine · 2021Article
- Elevated Expression of theCancers · 2021Article
- Review
- Receptor for Advanced Glycation End Products (RAGE) and Its Polymorphic Variants as Predictive Diagnostic and Prognostic Markers of NSCLCs: a Perspective.Current oncology reports · 2021Review
- The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in combined pulmonary fibrosis and emphysema (CPFE) in Japanese patients.Scientific reports · 2020Article
- Identification of genes associated with cancer progression and prognosis in lung adenocarcinoma: Analyses based on microarray from Oncomine and The Cancer Genome Atlas databases.Molecular genetics & genomic medicine · 2019Article
- Determination ofDisease markers · 2019Article
- Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis.International journal of general medicine · 2019Article
- The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.Oncology letters · 2018Review
- A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.Oncotarget · 2017Article
- All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.Paediatric respiratory reviews · 2017Review
- Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review.BMC cancer · 2017Review
- Silencing of advanced glycosylation and glycosylation and product-specific receptor (RAGE) inhibits the metastasis and growth of non-small cell lung cancer.American journal of translational research · 2017Article
- New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2017Article
- Effect ofCancer cell international · 2017Article
- Protein transduction therapy into cochleae via the round window niche in guinea pigs.Molecular therapy. Methods & clinical development · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receptor for advanced glycation end products (RAGE) is associated with the pathogenesis of cancer progression. The pathological effects mediated through RAGE are physiologically inhibited by soluble RAGE (sRAGE). The aim of the present study was to identify the expression of the sRAGE, RAGE and RAGE ligands in serum samples and lung cancer tissue obtained from lung cancer patients. Using ELISA and immunohistochemistry, it was observed that the sRAGE levels were downregulated in the serum, the expression of RAGE was decreased in the lung cancer tissue and the RAGE ligands HMGB1 and S100 were upregulated in cancer tissue. Furthermore, the presence of several selected types of RAGE polymorphism that occur in lung cancers were measured in the tissue samples. An association between the -429T/C and 2184A/G polymorphisms of RAGE and the genesis and progression of lung cancer was identified. The comparison between various histological subtypes and stages of lung cancer was performed with the aim to clarify the biological role of the RAGE gene, and identify a biomarker to aid diagnosis and predict the prognosis for lung cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.